Cure CMD 2010 CMD Family Conference Mission & Goals Roadmap Treatment.

Slides:



Advertisements
Similar presentations
Cancer Research UK strategy and funding Simon Vincent.
Advertisements

EU rare diseases registry for Niemann-Pick Disease type A, B and C Tarekegn Hiwot Consultant in Inherited Metabolic Disorders University Hospital of Birmingham.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.
Influencing Change in Research, Treatment Protocols, and New Drug Development.
Spondylitis Association of America 20 Years of Setting the Course.
HOSA State Advisors Management Conference 9/24/14.
Therapeutics for the Muscular Dystrophies.  Mission  Increase the longevity and quality of life of patients with muscular dystrophy  Lead Drug Candidate.
Nanotechnology in Drug Discovery- Development and Delivery
ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Pharmacogenomics: Implications for CNS Drug Development in the 21st Century Challenges for Development & Approval – Patient & Funding Agency Perspective.
Help build a research resource for scientists studying Congenital Muscular Dystrophy.
Supporting research and patient outreach for FacioScapuloHumeral Muscular Dystrophy (FSHD), one of the most common forms of muscular dystrophy. Progress.
INTERNATIONAL MYELOMA FOUNDATION
Introducing Sarcoma UK Roger Wilson. First steps … Roger Wilson – patient (dx 1999) –Journalist Sarcoma UK launched as newsletter –First edition April.
Nairobi, Kenya June 26, 2013 ROLE OF THE WFH, IN ACHIEVING TREATMENT FOR ALL.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Alzheimer’s Society, UK Our research programme
2010 CMD Family Conference Live CMD Learn CMD Connect CMD.
1 Transforming JDRF Research. Impacting Lives. Julia L. Greenstein, PhD AVP Cure Therapies April 10, 2012.
A baby will never know her mother’s touch How can you value this loss?
Public and patient priorities for research: an international perspective Astrid van der Schot Marco Blom Alzheimer Nederland Glenn Rees Ellen Skladzien.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
CPTR Overview CPTR 2012 Workshop October 2-4, 2012.
Amyotrophic Lateral Sclerosis (ALS)
Task Shifting in Malawi around delivery of antiretroviral therapy Anthony D Harries “The Union” Paris, France.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
RARE / ORPHAN DISEASES “ARE WE READY FOR THE CHANGE THAT WE NEED TO FIND EFFECTIVE TREATMENTS FOR ORPHAN DISEASE?”
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
The CMD genes ~ The CMD to LGMD spectrum CMDLGMD Ullrich CMD (col6a1, col6a2, col6a3) Bethlem myopathy Merosin deficient CMD (LAMA2) Dystroglycanopathies:
Pathways to Safety (DR) In Monterey County A Community-Based Early Intervention Initiative.
What is gene therapy? Do now: In your own words,
Dr Godfrey Grech University of Malta
A baby will never know her mother’s touch How can you value this loss?
An Introduction to Genetic Alliance UK’s Work in Scotland Natalie Frankish – Development Officer for Scotland Event:Action Duchenne Scottish Conference.
What is motor neurone disease? A fatal, rapidly progressive disease that affects the brain and spinal cord. Attacks the nerves that control movement so.
CMD International Registry CMD Family Conference August 2010 Ami Mehta, MS, CGC
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
A patient’s perspective on user fees Perry D Cohen PhD Parkinson Pipeline Project November 14, 2005.
Consumer Advocate Perspective Clinical Trials Registration Sharon F. Terry, JAM Sharon F. Terry, JAM President and CEO, Genetic Alliance, Inc. Founding.
ICARE Member Reports National Institutes of Health/National Institute of Neurological Disorders and Stroke NIH Mission: NIH is the steward of medical and.
Biomarker introduction Annemieke Aartsma-Rus November
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.
Recent Studies Funded by the Progressive MS Alliance Tim Coetzee, PhD ACTRIMS 2016.
WHAT WE HAVE LEARNED! John W. Day, MD, PhD Professor of Neurology and Pediatrics – Stanford University.
NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.
Outcomes – Gaye Powell. * “... a predicted measure of change that demonstrates a valid and significant therapeutic impact following an agreed intervention.”
Evidence-Based Mental Health PSYC 377. Structure of the Presentation 1. Describe EBP issues 2. Categorize EBP issues 3. Assess the quality of ‘evidence’
UPDATE ON SCA RESEARCH George Wilmot, MD, PhD. DISCLAIMER  The information provided by speakers in any presentation made as part of the 2016 NAF Annual.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
Partners in Progress: Deciding to Participate in Parkinson’s Clinical Research.
Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
How Charitable Organisations Support Research Presentation By: Sue Farrington Monday 10th October 2016.
Myotonic Dystrophy Research: What’s Next
OMICS Journals are welcoming Submissions
Update of the Scientific Secretariat
REPURPOSING - SOCIAL IMPACT BONDS FOR MEDICINE
Support- IRDiRC Proposed Work Plan And Communication Strategy
Introduction HCU Network Australia is a not for profit established in 2014 with the vision “to be a driving force in the journey to a cure, improving quality.
Myotonic Dystrophy Foundation
Being an effective consumer of preclinical research
-LIVE Global Activities-
From Bench to Clinical Applications: Money Talks
But There is Hope and Progress…..
This research PowerPoint template is good for use through July 31, For questions, please contact Amy Madsen, MDA marketing communications manager,
Presentation transcript:

Cure CMD 2010 CMD Family Conference Mission & Goals Roadmap Treatment

Mission To raise CMD awareness and identify treatments for the CMDs The men who build the future are those who know that greater things are yet to come, and that they themselves will help bring them about. Their minds are illuminated by the blazing sun of hope. They never stop to doubt. They haven’t time. ~Micheal Egan

Cure CMD Mission Treat/Cure Fund and Focus Research Biospecimen Repository Animal Model and Cell systems HTS Drug Pipeline

Cure CMD Goals: Discover Fundraise Treat

Goal 1: Discover CMD GoalTask CMDIRRegister global population CMD New GenesIdentify CMD Diagnostic Guidelines Publish and distribute BiomarkersFind and validate Natural HistoryLaunch CMD ResearchFund CMD BioBankDonate and grow

CMDIR Recently endorsed by AFM, Muscular Dystrophy Campaign (UK), Muscular Dystrophy Australia 23 countries represented Translated into: Portuguese, Spanish, German, French, English (Danish and Turkish forthcoming) Global registration= Power in Numbers and a Genetically Characterized Population

CMD New Genes Ongoing international effort to identify new genes with a particular focus on: a. Collagen VI like picture without collagen VI Mutation b. Dystroglycanopathy without 1/6 known gene mutations identified New Genes= New Targets

CMD Diagnostic Guidelines CMD Standard of Care Committee, Brussels, Nov CMD Care Guidelines 2. CMD Diagnostic Guideline Cure CMD is working with Dr. Sparks and Dr. Susana Quijano Roy to revise Genetest Diagnostic Guidelines= Recognition, Less Diagnostic Odyssey, Increased Rates of Genetic Confirmation of CMD community

CMD Biomarkers A biomarker is “something” you find in the blood, urine or muscle or on imaging that helps you track or mark disease progression OR improvement Biomarkers help a doctor monitor a disease Biomarkers help a scientist tell if a drug is working Biomarkers help confirm if a person who is treated says they feel stronger that there is a positive effect at the muscle level Biomarkers can given information about rate of disease progression Biomarkers can help a doctor titrate medication dose Biomarkers= Showing an Effect or Rate of Disease Progression on a Cellular or Organ System Level

CMD Natural History Follow people with CMD over time, looking at biomarkers, outcome measures and imaging To lead to this: CMD Translational Grant: Jim Collins, Biomarkers, Jan 2010 CMD Quality of Life Survey, March 2010 ENMC CMD Outcome Measure Meeting, March 2010 CMD Comparative Outcome Measure study, June 2010 NINDS and CMD: Common Data Elements Meeting, Sept 2010 CMD Motor Outcome Measure Meeting, October 2010 Natural History Study=Validation of Outcome Measures, Increases Ability to Measure Drug Effect

CMD Research Partnered with SAM in 2009 to fund >200K in CMD Research CMD Scientific Conferences: July 2009 Therapeutic Targets in the CMDs Jan 2010 CMD High Throughput Screening, NCGC Cure CMD SMAB, Sept 2010 Evaluate critical needs, direction and funding priorities Funding Research=Power to Identify and Evaluate Future Targets

Goal 2: TREAT CMD GoalTask CMD Care Guidelines Publish and distribute CMD Lay Guidelines Develop and Distribute Types of CMDDevelop video library Pulmonary care Develop video library

Goal 3: Fundraise CMD CanMakeDonation

Upcoming Events Tully’s Run for Owen, August 21, 2010 Cure CMD Team ~San Jose Rock N Roll ½ Marathon, October 3, 2010 Rage Against the Disease Art Auction, October 10, 2010 Cure CMD Team~Los Angeles Rock N Roll ½ Marathon, October 24, 2010 Cure CMD Team ~Long Branch ½ Marathon, May 1 st, 2011

Mission & Goals Roadmap Treatment

Stay on Mission, Build the Community, Prepare for clinical trials Family CMDIR CMD Family Conference CMD Lay Guidelines Scientist Annual Scientific Meetings Fund Translational Research Animal models, Biomarkers CMD BioBank Clinician SOC Care Guidelines Outcome Measures Biomarkers

Manage a Roadmap Preclinical Trials Clinical Trials What target? What endpoints? What delivery system? How big is the effect? What preliminary data? Combination therapy? What validation workflow?

CMD Target Roadmap Drug or Mechanism Preclinical: HTS animal model Valley of Death: funding toxicology preclinical studies drug manufacture Clinical Trials: funding Laminin 111 X X Omigapil X X N- Acetylcysteine X X IPLEX/IgF X Upregulation glycosylation X Upregulation CT Gal NAC transferase activity X

Clinical Trial Readiness Clinical Trials Natural History StudyBiomarkers Outcome Measures Defined patient cohorts Refine clinical trial design

Clinical Trials Holy grail is not clinical trials, it is a treatment that works. To objectively determine a treatment works, we go through clinical trials. Right drug, right population. We cannot afford a major learning experience at the clinical trial level.

Treatments Clinical Trial Readiness Collaborations Roadmap